The global glaucoma treatment market was valued at USD 5.7 billion in 2022 and is projected to grow steadily throughout the forecast period from 2023 to 2033, at a compound annual growth rate (CAGR) of 3.18%. By the end of 2033, the market is expected to reach approximately USD 8.0 billion, driven by advancements in treatment options, increasing awareness, and the rising global prevalence of glaucoma.
Glaucoma, a leading cause of irreversible blindness, is prompting higher demand for effective treatments such as eye drops, oral medications, and surgical procedures. As the aging population grows and more people are diagnosed with glaucoma, the market is witnessing increased adoption of innovative therapies aimed at lowering intraocular pressure and preventing further vision loss.
In addition to traditional therapies, novel treatments, including minimally invasive surgeries and laser therapies, are gaining traction. These innovations are enhancing the effectiveness and safety of glaucoma treatment, further contributing to the market’s growth. Moreover, improvements in diagnostic technologies and rising awareness about the disease are expected to drive early diagnosis and treatment, positively impacting market dynamics.
Request a Sample Report Now to get Premium Insights: https://www.fmisamplereport.com/sample/rep-gb-14351
Key Takeaways:
- The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR of 3.18%.
- Increasing glaucoma prevalence, especially among the aging population, is driving demand for effective treatments.
- Novel treatments and minimally invasive procedures are contributing to the market’s expansion.
- Rising awareness and advancements in diagnostic technologies are expected to further boost market growth.
Competitive Landscape
The key companies in the glaucoma treatment are concentrating their efforts on partnerships and collaborations as the primary means of increasing their geographical presence. These will aid market participants in expanding both their new product launch and market penetration.
- Teva Pharmaceuticals announced the first generic version of AZOPT (brinzolamide ophthalmic suspension) 1 percent in March 2021 in the United States to treat open-angle glaucoma and ocular hypertension. The company’s product portfolio has been strengthened as a result of this.
- Aerie Pharmaceuticals and Santen Pharmaceuticals entered into a partnership agreement in December 2021. This partnership will lead to development and marketing of product for glaucoma therapy which included Rhopressa/Rhokiinsa and Rocklatan/Roclanda. Both companies are set to commercialize these products across various geographies including India, Europe, Oceania, China, and parts of Latin America, thereby strengthening their current market positioning in these regions.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the glaucoma treatment market, which are available in the full report.
Key Companies Profiled
AERIE Pharmaceuticals, Inc.; Cipla Inc.; Akorn Operating Company LLC; AbbVie; Bausch & Lomb Incorporated; Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.
Key Market Segments Covered in Glaucoma Treatment Market Research
By Disease Type:
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Other
By Drug Class:
- Prostaglandin Analog
- Beta Blockers
- Adrenergic Agonist
- Carbonic Anhydrase Inhibitors
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
